新型冠狀病毒疫苗meta分析
首發時間:2021-09-02
摘要:目的評價新型冠狀病毒疫苗的有效性及安全性。方法電子檢索PubMed、Web of sciense,The Cochrane Library,并輔以手工檢索相關雜志和納入研究的參考文獻,對國內外公開發表的符合入選標準的新冠疫苗Ⅰ期Ⅱ期或Ⅲ期臨床試驗數據的研究文獻,共納入12篇文獻,利用Revman 5.4和Stata 16.0軟件進行Meta分析。結果有效性:輝瑞疫苗>Moderna疫苗>Gamaleya研究所疫苗>北京生物制品研究所疫苗>武漢生物制品研究所疫苗>康希諾疫苗>阿斯利康/牛津疫苗>強生公司疫苗>科興疫苗;不良反應發生率:核酸疫苗>病毒載體疫苗>滅活疫苗。本文為新冠疫苗受眾者的選擇和決策提供了科學依據,對新冠疫苗相關知識的普及也具有參考價值。
For information in English, please click here
Meta-analysis of Covid-19 vaccine
Abstract:Objective: To evaluate the efficacy and safety of novel Coronavirus vaccine.Methods: PubMed, Web of Sciense and the Cochrane Library were searched electronically, supplemented by manual retrieval of relevant journals and included studies. The 12 published literature of phase I, II or III clinical trials of COVID-19 vaccine meeting the inclusion criteria was reviewed.The meta-analysis was performed using Revman 5.4 and Stata 16.0 software.Results: Efficacy: Pfizer vaccine > Moderna Vaccine > Gamaleya Vaccine > Beijing Institute of Biological Products vaccine > Wuhan Institute of Biological Products Vaccine > Concino vaccine > Astrazeneca/Oxford Vaccine > Johnson & Johnson vaccine > Sinovac;Incidence of adverse effect: nucleic acid vaccine > viral vector vaccine > inactivated vaccine.This work provides a systematic basis for the selection and decision-making of COVID-19 vaccine audiences, and is also of reference value for the popularization of COVID-19 vaccine related knowledge.
Keywords: COVID-19 vaccine Meta analysis;COVID-19
基金:
引用
No.****
動態公開評議
共計0人參與
勘誤表
新型冠狀病毒疫苗meta分析
評論
全部評論